Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018183956) NAPHTHYRIDINES AS INHIBITORS OF HPK1
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/183956 International Application No.: PCT/US2018/025562
Publication Date: 04.10.2018 International Filing Date: 30.03.2018
IPC:
C07D 471/04 (2006.01) ,C07D 519/00 (2006.01) ,A61K 31/4375 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
519
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/ or C07D455/257
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
4375
the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
GENENTECH, INC. [US/US]; 1 DNA Way South San Francisco, California 94080, US (US)
F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124 4070 BASEL, CH (AllExceptUS)
Inventors:
CHAN, Bryan; US
DANIELS, Blake; US
DROBNICK, Joy; US
GAZZARD, Lewis; US
HEFFRON, Timothy; US
HUESTIS, Malcolm; US
LIANG, Jun; US
MALHOTRA, Sushant; US
MENDONCA, Rohan; US
RAJAPAKSA, Naomi; US
SIU, Michael; US
STIVALA, Craig; US
TELLIS, John; US
WANG, Weiru; US
WEI, BinQing; US
ZHOU, Aihe; US
CARTWRIGHT, Matthew W.; GB
GANCIA, Emanuela; GB
JONES, Graham; GB
LAINCHBURY, Michael; GB
MADIN, Andrew; GB
SEWARD, Eileen; GB
FAVOR, David; CN
FONG, Kin Chiu; CN
HU, Yonghan; CN
GOOD, Andrew; CN
HU, Baihua; CN
LU, Aijun; CN
Agent:
TIAN, Zong-Qiang Bill; US
ACKERMAN, Lily J.; US
AUSENHUS, Scott L.; US
BERENDT, Frank JN; US
BUCKWALTER, Brian L.; US
CHANG, Y. Elaine; US
CHI, I. Shannon; US
CLARK, Kevin M.; US
COBURN, Cara M.; US
COLANTINO, Jessica R.; US
CRISSEY, Todd M.; US
CUI, Steven; US
DAVIS, Jennifer L.; US
DUFFIELD, Jonathan J.; US
FANG, Carol A.; US
GHOSE, Shameek; US
HALL, Robert C.; US
HEIDER, Julie A.; US
HILL, Laurie L.; US
HOLMES, Jennifer K.; US
JOHNSTON, Sean A.; US
KAFKA, Mark D.; US
KALE, Tamara A.; US
KALINOWSKI, Grant E.; US
KUBINEC, Jeffrey S.; US
LEE, Wendy M.; US
LI, Qianru; US
MARSCHANG, Diane L.; US
MCCLELLAN, Kelly B.; US
PAZDERA, R. Minako; US
RICHARDSON, Jessica L.; US
ROPP, Traci H.; US
SCHWARTZ, Timothy R.; US
SHERMAN, Daniel E.; US
SHIN, Elinor K.; US
TAN, Anna M.; US
WAIS, Rebecca J.; US
YEUNG, Bonny G.; US
DREGER, Ginger; US
Priority Data:
PCT/CN2017/07879230.03.2017CN
PCT/CN2018/07690915.02.2018CN
Title (EN) NAPHTHYRIDINES AS INHIBITORS OF HPK1
(FR) NAPHTYRIDINES UTILISÉS EN TANT QU'INHIBITEURS DE HPK1
Abstract:
(EN) Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
(FR) L'invention concerne des composés de naphtyridine et leur utilisation en tant qu'inhibiteurs de HPK1. Les composés de l'invention sont utiles dans le traitement de troubles dépendant de HPK1 et l'amélioration d'une réponse immunitaire. L'invention concerne également des procédés d'inhibition de HPK1, des procédés de traitement de troubles dépendant de HPK1, des procédés d'amélioration d'une réponse immunitaire, et des procédés de préparation des composés de naphtyridine.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)